The Bombay High Court’s decision in Ms. C.B. Healthcare and Ors. v. Union of India is a significant reminder that prosecutions under the Drugs and Cosmetics Act, 1940 must satisfy not only public health objectives but also the statutory safeguards built into the Act and the Rules. In a judgment delivered on 24 March 2026, Justice N.J. Jamadar quashed the criminal prosecution against the manufacturer and its partners, holding that the cumulative procedural lapses had destroyed the accused’s valuable right to challenge the analyst’s report and had rendered the continuation of prosecution an abuse of the process of court.

